Feb. 19, 2020 /CNW/ -- Nimble Therapeutics, Inc. today announced a multi-year collaboration with Genentech, a member of the Roche Group, to accelerate discovery and development of novel peptide ...

Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across ...

--(BUSINESS WIRE)--Nimble Therapeutics announced that Dan Flynn and Brian Cali have joined the company’s Board of Directors. Both bring deep entrepreneurial and drug development track records ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...